{"entity":{"id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","aka":[],"tldr":"A phase 3 trial of 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) in advanced solid tumours, run by National Vaccine and Serum Institute, China, now recruiting.","summary":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years is a phase 3 interventional study registered as NCT05262010 by National Vaccine and Serum Institute, China, with 13500 participants planned, started 2022-06-04 and due to reach its primary completion in 2028-06. Interventions recorded: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) and placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05262010","url":"https://clinicaltrials.gov/study/NCT05262010"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05262010","phase":"3","setting":"A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","sponsor":"National Vaccine and Serum Institute, China","enrolled":13500,"outcomes":[]},"route":"/trials/nct05262010/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}